Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $20.63B | $2.08B | $4.56 |
| 2024 | $19.67B | $1.99B | $4.37 |
| 2023 | $19.55B | $1.57B | $3.04 |
| 2022 | $18.34B | $1.92B | $4.22 |
| 2021 | $17.59B | $2.25B | $4.90 |
Social Signal Score
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $1.21 per share
Typical surprise +8.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$1.13 vs $1.04beat
- Wed, Apr 29$0.99 vs $1.04miss
- Wed, Feb 4$1.44 vs $1.40beat
- Wed, Oct 29$1.07 vs $1.05beat
- Wed, Jul 30$1.06 vs $0.92beat
- Wed, Apr 30$1.01 vs $0.91beat
Estimates and results for GEHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GEHC's reported EPS growth of -1.8% a year over 4 years.
- EPS in 5 years
- $4.17
- Implied price
- $75.04
- Return from $73.69
- 0.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $37.31 — -49.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -11.8% | -16.9% | -13.1% | -9.9% | -7.0% | -4.5% |
| -6.8% | -12.2% | -8.2% | -4.7% | -1.8% | 0.9% |
| -1.8% | -7.5% | -3.2% | 0.4% | 3.5% | 6.3% |
| 3.2% | -2.7% | 1.7% | 5.5% | 8.8% | 11.7% |
| 8.2% | 2.0% | 6.6% | 10.6% | 14.0% | 17.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (3)
- Newszacks.com·2d ago·Neutral
GEHC or LMAT: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·3d ago·Positive
GE HealthCare (GEHC) Upgraded to Buy: Here's What You Should Know GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·4d ago·Positive
GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average GE HealthCare Technologies (GEHC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GEHC broke through the 200-day moving average, which suggests a long-term bullish trend.
View source ↗